FDA advisory committee votes again higher dose of Lilly-Incyte arthritis drug

In a mixed decision, the panel voted in favor of approving a lower, 2 milligram (mg) dose of the drug, baricitinib, for the treatment of rheumatoid arthritis.

April 24, 2018

Developed by Eli Lilly and Incyte, rheumatoid arthritis drug baricitinib suffered a setback as an advisory committee to the U.S. Food and Drug Administration voted against approval of a 4-milligram dose. The committee did however vote in favor of approving a lower, 2 milligram (mg) dose.

The vote came a year after baricitinib was already rejected by the FDA, citing safety concerns.

Read the Retuers report